Eupraxia Pharmaceuticals (EPRX) Stock: Buy, Sell, or Hold?
EPRX - Eupraxia Pharmaceuticals Inc. Common Stock
$7.73
0.14 (1.84%)
▲
5d:
+17.3%
30d:
-9.91%
90d:
+22.7%
BUY
HIGH Confidence
Analysis Updated: Oct 20, 2026 12:00 AM ET
Earnings: Nov 03, 2026
12d
Get Alerted When EPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EPRX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: EPRX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: EPRX is currently trading at $7.73, which is considered fair relative to its 30-day fair value range of $7.14 to $8.43.
Technical Outlook: Technically, EPRX is in a strong uptrend. The price is approaching resistance at $7.76. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EPRX scores 80/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.35 (+115.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EPRX is in a strong uptrend. The price is approaching resistance at $7.76. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EPRX scores 80/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.35 (+115.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.14 -
$8.43
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (80/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 115.4% below Wall St target ($16.35)
- BULLISH: Bottoming setup score 80/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$7.14 -
$8.43
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.42
Resistance Level
$7.76
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.32
Wall Street Target
$16.35
(+115.4%)
Share & Embed Analysis
Last updated: October 21, 2026 4:32 PM ET
Data refreshes hourly during market hours. Next update: 5:32 PM
Data refreshes hourly during market hours. Next update: 5:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 55 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 61 BUY |
